Explore the options in indolent non-Hodgkin lymphoma (iNHL) with the experts with this live, interactive meeting. Stay informed on the treatment and management of iNHL in high-risk patients, those with co-morbid conditions, and patients with potential contraindicated drugs. Expert faculty will focus on case discussion and the latest, clinically relevant data.
1.0 AMA PRA Category 1 Credit™
This meeting series has ended.
|6.30 PM||Registration and dinner|
|6.45 PM||Indolent non-Hodgkin lymphoma (iNHL) in 2017: Considerations for therapy|
|6.55 PM||Q & A|
|7.00 PM||Managing the hard-to-treat patient with iNHL|
|7.40 PM||Q & A|
|7.45 PM||prIME Points™|
Danielle Brander, MDDuke Cancer Institute
Duke University School of Medicine
Durham, North Carolina, United States
Jonathon B. Cohen, MD, MSEmory University
Winship Cancer Center
Atlanta, Georgia, United States
Alexey Danilov, MD, PhDOregon Health & Science University
Portland, Oregon, United States
Brett Gourley, MDRockwood Cancer and Blood Specialty Center - North
Spokane, Washington, United States
Anthony Mato, MD Memorial Sloan Kettering Cancer Center
New York, New York, United States
Loretta Nastoupil, MDThe University of Texas
MD Anderson Cancer Center
Houston, Texas, United States
Mazyar Shadman, MD, MPHFred Hutchinson Cancer Research Center
University of Washington
Seattle, Washington, United States
This activity has been designed to meet the needs of medical oncologists and hematologists, nurses, physician assistants, nurse practitioners, and other healthcare professionals who treat or manage patients with iNHL.
After successful completion of this educational activity, participants should be able to:
- Select optimal therapy based on patient and disease characteristics
- Identify proper sequence of therapeutic options for specific patients
- Compare side effect profiles of targeted therapies and select the most appropriate treatment based on patient and disease characteristics
This educational activity is supported by a grant from Gilead Sciences, Inc.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of prIME Oncology. prIME Oncology is accredited by the ACCME to provide continuing medical education for physicians.
prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is provided by prIME Oncology.
prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.